



## **50** years of innovation:

Helping you take on the challenges of tomorrow

Front cover photo by Nathan Dumlao on Unsplash https://unsplash.com/@nate\_dumlao?utm\_ source=unsplash&utm\_medium=referral&utm\_ content=creditCopyText

### References

- McKie, P.M. et al. (2016). J Am Coll Cardiol 68(22), 2437-2439.
- 2 Zeisler, H., Llurba, E., Chantraine, F. et al. (2016).
- 3 Tina-quant Hemoglobin A1c Gen. 3 package insert. Roche Diagnostics. 2018.

COBAS, ELECSYS and TINA-QUANT are trademarks of Roche.

© 2018 Roche

### Published by:

Roche Diagnostics International Ltd CH-6343 Rotkreuz Switzerland

diagnostics.roche.com







## **50** years of innovation

# *Putting the laboratory at the centre* of healthcare to come

Roche Diagnostics is dedicated to helping clinical laboratories lead the way in healthcare transformation and meet the challenges of a changing world. Over half a century, we have developed a unique range of market-leading Serum Work Area solutions and personal consultancy packages to help you seek greater efficiency and accuracy in every detail, with benefits that reach far beyond the laboratory. From components and innovative assays to cutting-edge technology and smart automation, you can make our experience your advantage, helping diagnostics drive the future of healthcare to come.



#### Partnership Roche - Hitachi

The origin of pioneering diagnostic innovations from Roche began 40 years ago, when Hitachi and formerly Boehringer Mannheim teamed up for the sales and development of automated analyzers for clinical laboratory testing of body fluids. Since the introduction of the Hitachi 706 D to the German market in 1978, a new generation of automated analyzers paved the way to an unbroken sequence of industry's first innovations under the name of cobas®.

1978



#### Launch of COBAS INTEGRA®

We launched COBAS INTEGRA® in 1995 that introduced innovation via integration of multiple testing technologies (ISE, photometric and fluorescence polarization) in the one analytical system. The COBAS INTEGRA® cassette is additionally the forefather of today's cobas c pack.

1995



#### First consolidated SWA solution: MODULAR **ANALYTICS**

We pioneered the concept of the Serum Work Area (SWA) in 2002 by being the first company to integrate Clinical Chemistry with Immunoassay testing in a modular and scalable system to help consolidate workload and maximize lab efficiency.

2002



### cobas® family pioneering common reagent and platform concept

With the launch of cobas® 6000 in 2006, we were the first to introduce a common reagent and system platform. This gives healthcare organizations exactly what they need: analytical platforms that satisfy low-, medium- and high-volume testing needs all standardized on the same reagents, detection methodology, and software system.

2006



Tina-quant® Lp(a) Gen. 2 The first method in the world to accurately and reliably measure Lp(a) on a fully consolidated platform independent of the molecular weight.

**2013** 



#### cobas c 513 analyzer, first fully automated high throughput **HbA1c solution**

This dedicated, fully automated high throughput HbA1c solutions sets a new precedent in HbA1c testing efficiency.

2015



### 50th anniversary of Roche **Clinical Chemistry**

Roche has more than 50 years' experience in developing Clinical Chemistry reagents which have made a difference in people lives in the past 50 years. Our unique reagent concept, robust standardization strategy and innovation for medical value, helps our customers to face their clinical chemistry testing with confidence, now and in the future.

2019





### 1969

#### Roche enters diagnostics market

The creation of a department for diagnostic product marks Roche's entry into a new sector. Apart from developing new diagnostic tests and automatic analyzers. objectives include setting up service laboratories to perform clinical analyses for hospitals and office-based physicians.



### 1989

#### Accelerated acute myocardial infarction (AMI) diagnosis

The development of Troponin T. and in following years Troponin T-high sensitive, has improved the diagnosis of AMI worldwide. With earlier diagnosis, critically ill patients are able to receive life-saving therapy sooner, helping deliver improved patient care.



### 1996

## Roche brought the Elecsys® technology to the market

Elecsys® technology

with the first Elecsys analyzer. Without doubt, the Elecsys® technology and the assays have set highest standards in immunochemistry and the perfect fit of cobas® systems and Elecsys® technology have driven the tremendeous success story in the market.



### 2003

#### "Gold Standard" biomarker for heart failure

Roche drove the development of NT-proBNP which is now considered the "Gold Standard"1 biomarker for diagnosing and managing heart failure. The development of NT-proBNP, and the substantial level of clinical evidence supporting its clinical value, has improved the lives of millions of heart failure patients globally.



### **2010**

#### Launch of sFlt-1 and PIGF assays for use with preeclampsia

First to market with a fully automated solution for testing sFlt-1 and PIGF to guide clinical management in preeclampsia. The ratio between the two Elecsys® assays, combined with assay specific cut-offs from the PROGNOSIS study (2016), continues to provide upparalleled medical value to patients and clinicians.2



### **2013**

### Tina-quant® HbA1c Diagnosis

Roche developed the high quality Tina-quant® HbA1c test for consistent, early, and accurate diagnosis and monitoring of diabetes 3 It delivers the accuracy precision, automated analyses, and simplicity that allows you to achieve the medical value and workflow efficiency you need most.



## 2018

## cobas pro integrated solutions

Launch of cobas pro

represents the starting point of a new generation of serum work area solutions, with a unified reagent concept, seamlessly integrated into the Roche Integrated Core Lab